CardioTech adds smaller size to artificial heart bypass graft trial
This article was originally published in Clinica
Executive Summary
CardioTech International has received US FDA approval to add a 4mm graft to the European clinical trial of its artificial heart bypass vessel, CardioPass. The 10-patient study, which started around 15 months ago, previously used only a 5mm graft. Eric Walters, the Wilmington, Massachusetts firm's vice-president and chief financial officer, told Clinica that including the smaller size will widen the pool of patients eligible for enrolment. The firm hopes to report results within a year, which, if positive, will support CE marking of CardioPass for sale in Europe. CardioTech will then consider applying for FDA clearance, Mr Walters said.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.